Caitlin Cameron

Caitlin Cameron is the Chairman & CEO at Otometrix Medical Technologies, a position they have held since 2013. Prior to this, they were the President & Chief Executive Officer at Presage Biosciences, Inc. from 2010 to 2012.

At Presage Biosciences, Ms. Cameron was responsible for building the start-up biosciences company to commercialize technologies developed at the Fred Hutchinson Cancer Research Center. This involved leading the build-out of laboratory facilities, creating research capabilities, and entering into strategic alliances with major pharmaceutical companies to integrate Presage technology into their cancer drug development processes.

Under Ms. Cameron's leadership, Presage Biosciences closed $6.5 million in pure Angel funding in two rounds, brought in 50 investors, and preserved the company's capital structure, thus minimizing dilution. Ms. Cameron was also responsible for all aspects of Executive management, including funding attainment, investor relations, building of management and scientific teams, strategic and tactical planning, and results achievement.

Thanks to Ms. Cameron's strategic vision, Presage Biosciences entered into partnership alliances with top-5 Big Pharma companies who utilized Presage technology to identify new drug combinations worth potentially billions in new revenue and representing significant advances in cancer treatments. Additionally, Presage Biosciences was able to screen early-stage drug candidates to predict which candidates would prove to show efficacy in human clinical trials years in advance of such trials, potentially saving hundreds of millions of dollars and years of wasted effort on drug candidates that would later fail in human clinical trials.

Some individuals on their team include Lisa LaFleur - SVP, Research, Mark A. Moehring - Co-Founder & Chief Science Officer, and John Alleman - Chief Technology Officer.